glucose tolerance test (IVGTY) in man has been the target of an awesome amount of research over the past 30 years and more recently has come back into sharp focus due to possibilities that this maneuver, or some variant thereof, may be an important predictor of Bcell failure associated with Type 1 (insulin-dependent) diabetes.
Just as beauty is in the mind of the beholder, high variability (a difficult statistical concept and a more difficult one to quantify) may also be in the mind of the beholder. Many data sets when viewed by one investigator may be thought to be highly variable, whereas another group may construe the same data set as being quite reproducible.
The study by Smith and colleagues focussed upon an important statistical aspect; however, there are some components of that study that deserve careful examination. As biological functions are usually anticipated to be variable, studies performed on eight subjects may be insufficient in number to derive meaningful conclusions. Earlier [3] we had attempted to quantify variability with 42 normal control subjects and 36 study subjects. We felt uncomfortable at such low numbers of subjects at that time.
With such a limited number (n =8) of subjects and without any background studies of single IVGT1 ~ that the laboratory might have performed in a larger group of healthy control subjects, it is uncertain whether the eight subjects selected represent sampling that is typical of the normal distribution, or whether they cluster toward the high or low end. Magnitude effects upon the variability might therefore be an important consideration which is masked in the design of this current study.
Although we are grateful that one of our previous studies on this subject was cited [4] , a survey of six of our other publications (see 5, a review) may have allowed for the development of a different posture. We have examined early phase insulin responses after IVGTr in various high risk groups defining the high risk as not only a strong hereditary tendency to Type 1 diabetes (monozygotic twin or first degree relative) but have also insisted upon the presence in serum of some autoimmune abnormality such as the presence of islet cell autoantibodies. Using these subjects for IVGTr studies, it has been demonstrated that as a group, the early phase insulin response is significantly reduced when compared to a global normal population [61. In addition, repeated assessments of early phase insulin response to glucose in such subjects shows either a tendency to be reproducible (i.e. to show on repeat testing an impaired insulin response similar to the impairment of the initial one) or an early phase insulin response that is reduced even further [4] . One might construe that "poor reproducibility" with variability equally positive and negative of a large magnitude might be a sign of "normality" whereas "good reproducibility" or "'poor reproducibility but with a chronic negative bias" may be the hallmark of "non-normality".
Smith and colleagues state that the IVGTT capability of discriminating normal from abnormal results is largely dependent on the degree of between-and within-subject variation. Firstly, it is doubtful, even if this is true, that this could be established in studies focussed on eight healthy subjects. Secondly, when IVGTT-induced earlyphase insulin release is equal or less than the fifth percentile of that established in normal control subjects (hundreds of them), as we found in 17 of 28 (61%) high risk subjects on their initial test [7] and in 12 of 14 such individuals on repeat testing, then reproducibility per se appears to not be a relevent component of the assessment.
As more data is presented and published from a large number of laboratories, a reduced and fixed or consistently falling early-phase insulin release (1) in a subject with an appropriate genetic connection (2) to Type 1 diabetes and an autoimmune defect (3) consistent with Type 1 diabetes mellitus may be the key and critical marker that will serve not only to predict the onset of Type 1 diabetes but also, on the other hand, in immunosuppresive trials, to be the ultimate measure of the degree of success. I doubt that the biological variability of this exhibit of insulin release will cloud these issues. 
How do I get that abstract accepted?
Dear Sir, Since the very start of our EASD meetings, the number of submitted abstracts has increased steadily. Even this year, facing competition with the IDF meeting in Australia, the Programme Committee received more than 1000 abstracts for evaluation.
For the undersigned, it is the end of a 5-year tenure, the first two years as a member and the following three years as chairman of the Programme Committee. Each year, the end of March has been characterised by an increased weight of the envelopes arriving from Jim Jackson at the EASD Secretariat. More importantly, 1988 also marks the 5th anniversary of the Programme Committee evaluating the abstracts anonymously', i.e., without knowing who submitted the study. This is a remarkable procedure, and 1 have often been asked how a committee of five people is able to give a fair judgment of the quality of work and suitability for presentation when given over 1000 abstracts to read in a few weeks' time. The task would perhaps have been easier if the number of papers accepted for presentation had increased in direct proportion to the increasing number of abstracts submitted. However, this has not been the case. The number of papers to be presented has rcmained constant, at about 500-600, depending on the number of posters which the local organisers have been able to fit into the area designated for posters. As you all remember, the poster area may be spacious, as in Rome, or zig-zag cramped, as in Leipzig. Therefore, unless the EASD Council and the General Assembly decide to add an extra day or two (God forbid!) to our meeting, the number of presentations will remain constant. So, if the number of abstracts submitted continues to grow, how do you get your work accepted for presentation ?
As the outgoing chairman of the Progarmme Committee, I would like to offer some advice for future submissions. There is no guarantee that it will work, since who knows what the new Honorary Secretary will come up with to change the procedure in selecting abstracts.
During the past 3 years, ! have had the pleasure to work with eleven eminent diabetologists from 7 different European countries.
